Reports Q4 revenue $45.1M, consensus $44.33M. “Our strong performance and growth for LUPKYNIS throughout 2023 demonstrates the ongoing success of our commercial strategy. We will continue to focus on driving the upward trajectory of LUPKYNIS, while significantly reducing expenses and providing increased cash flow for 2024 and beyond. With our deeply experienced and dedicated team, we have built a strong foundation for Aurinia’s growth that will lead us into another high performing year. We are confident in the actions we have taken to drive increased shareholder value and will continue to act with urgency for the benefit of shareholders,” said Peter Greenleaf, CEO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AUPH:
- Aurinia Pharmaceuticals Announces Strategic Review Outcomes and Buyback Program
- AUPH Earnings this Week: How Will it Perform?
- Aurinia Pharmaceuticals call volume above normal and directionally bullish
- Aurinia Pharmaceuticals sees FY24 net product revenue $200M-$220M
- Aurinia Pharmaceuticals sees FY23 revenue about $176M, consensus $174.71M
